Onderneming BioCryst Pharmaceuticals, Inc.
Aandelen
BCRX
US09058V1035
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
4,21 USD | -3,88% | -8,08% | -29,72% |
Vakgebied
Aantal werknemers: 536
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Oral Small Molecule and Protein Therapeutics
100,0
%
| 271 | 100,0 % | 331 | 100,0 % | +22,37% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
87,0
%
| - | - | 288 | 87,0 % | - |
Non-United States
11,4
%
| - | - | 38 | 11,4 % | - |
Global
1,6
%
| 271 | 100,0 % | 5 | 1,6 % | -98,00% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01-01-07 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 02-04-20 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-22 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-09-19 |
Philip George
PRN | Corporate Officer/Principal | - | 01-09-22 |
Corporate Officer/Principal | - | 01-01-15 | |
Charles Gayer
PRN | Corporate Officer/Principal | 53 | 01-08-15 |
Human Resources Officer | - | 01-11-18 | |
Salisa Hauptmann
LAW | General Counsel | - | 01-01-21 |
Corporate Officer/Principal | 61 | 01-01-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 27-02-20 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01-01-07 |
Director/Board Member | 60 | 26-07-21 | |
Stephen Aselage
BRD | Director/Board Member | 73 | 04-01-19 |
Director/Board Member | 69 | 10-10-11 | |
Nancy Hutson
CHM | Chairman | 74 | 20-01-12 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-09-19 |
Steven Galson
BRD | Director/Board Member | 67 | 01-09-21 |
Theresa Heggie
BRD | Director/Board Member | 63 | 03-12-18 |
Amy McKee
BRD | Director/Board Member | 52 | 20-09-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 206 149 929 | 199 798 093 ( 96,92 %) | 0 | 96,92 % |
Bedrijfsgegevens
BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard Suite 200
27703-8457, Durham
+919 859 1302
http://www.biocryst.comSector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-29,72% | 868 mln. | |
-1,51% | 104 mld. | |
+3,22% | 97,42 mld. | |
+1,86% | 22,2 mld. | |
-16,53% | 21,23 mld. | |
-8,49% | 18,33 mld. | |
-42,33% | 16,35 mld. | |
-20,09% | 15,06 mld. | |
+5,47% | 13,98 mld. | |
+28,85% | 11,66 mld. |
- Beurs
- Aandelen
- Koers BCRX
- Onderneming BioCryst Pharmaceuticals, Inc.